UBS

Hua Medicine, the third biotechnology firm to list in Hong Kong, got across the finish line with an undersubscribed retail book, even though several blue-chip funds threw their weight behind the deal.

Issuers and debt bankers in Asia have their eyes fixed on the coming week for primary deal flow to gather momentum, following a relatively slow pace of issuance at the start of September.

China’s drug developer Luye Pharma Group has launched a $300m loan into general, to back the acquisition of two antipsychotic medical products.

The Asian follow-on and block markets saw two transactions in Chinese healthcare names this week that raised a total of $250m.

Qutoutiao and 111 have launched their respective IPOs on the Nasdaq this week, while Liulishuo has headed to New York for a listing.

Chinese mobile content aggregator Qutoutiao has hit the play button on its US IPO, targeting $144m from an offering of American Depository Shares (ADS).

Swiss healthcare company Roche took advantage of upcoming redemptions and a new investor base following its rating upgrade by Moody’s, to raise CHF900m ($922m) from a dual tranche offering.

Telecom infrastructure firm Circet Odyssee has joined the early September pipeline of deals in the euro leveraged loans market with a small tap. It will fund the buyout of Irish peer KN Group, with parent company Advent planning to merge the companies.

CPE Greenery has bagged HK$788.1m ($100.4m) after trimming its stake in Chinese drug maker Luye Pharma, according to a source close to the deal.

Meituan Dianping, one of China’s hottest technology unicorns, has launched bookbuilding for its up to HK$34.6bn ($4.4bn) Hong Kong IPO.

Biotechnology firm Hua Medicine has launched bookbuilding for its Hong Kong IPO, targeting up to HK$972.1m ($123.9m) in proceeds.

There was little in the way of emerging market bond issuance this week to set the tone for the usually busy month of September. Although mBank raised €500m of four year money, CEE-focused Atrium European Real Estate had yet to appear with a deal that had been planned for Thursday.